Cargando…

Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinib

BACKGROUND: ALK rearrangement-advanced NSCLC patients respond to crizotinib. ALK rearrangement is currently determined with RT-PCR. VENTANA IHC is a standard method to identify ALK protein overexpression in NSCLC; however, VENTANA IHC has rarely been used to determine the response to crizotinib in C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Chun-wei, Wang, Wen-xian, Chen, Yan-ping, Chen, Yu, Liu, Wei, Zhong, Li-hua, Chen, Fang-fang, Zhuang, Wu, Song, Zheng-bo, Chen, Xiao-hui, Huang, Yun-jian, Guan, Yan-fang, Yi, Xin, Lv, Tang-feng, Zhu, Wei-feng, Lu, Jian-ping, Wang, Xiao-jiang, Shi, Yi, Lin, Xian-dong, Chen, Gang, Song, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896026/ https://www.ncbi.nlm.nih.gov/pubmed/29642919 http://dx.doi.org/10.1186/s12967-018-1468-9

Ejemplares similares

Comparison of IHC, FISH and RT-PCR Methods for Detection of ALK Rearrangements in 312 Non-Small Cell Lung Cancer Patients in Taiwan
por: Wu, Yi-Cheng, et al.
Publicado: (2013)

Detection of EML4-ALK in Lung Adenocarcinoma Using Pleural Effusion with FISH, IHC, and RT-PCR Methods
por: Liu, Leilei, et al.
Publicado: (2015)

ALK-Rearranged Lung Cancer in Chinese: A Comprehensive Assessment of Clinicopathology, IHC, FISH and RT-PCR
por: Li, Yuan, et al.
Publicado: (2013)

Clinical Characteristics and Outcomes of Patients with Primary Lung Adenocarcinoma Harboring ALK Rearrangements Detected by FISH, IHC, and RT-PCR
por: Wang, Jinghui, et al.
Publicado: (2014)

Detection of lung adenocarcinoma with ROS1 rearrangement by IHC, FISH, and RT-PCR and analysis of its clinicopathologic features
por: Cao, Bing, et al.
Publicado: (2015)

Patients harboring ALK rearrangement adenocarcinoma after acquired resistance to crizotinib and transformation to small-cell lung cancer: a case report
por: Zhu, You-cai, et al.
Publicado: (2017)

Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative
por: Ma, Di, et al.
Publicado: (2016)

Anaplastic lymphoma kinase (ALK)-rearranged pulmonary pleomorphic carcinoma successfully treated with crizotinib
por: Lin, Liping, et al.
Publicado: (2018)

Heterogeneous responses and resistant mechanisms to crizotinib in ALK‐positive advanced non‐small cell lung cancer
por: Kang, Jin, et al.
Publicado: (2018)

Detection of ROS1 Gene Rearrangement in Lung Adenocarcinoma: Comparison of IHC, FISH and Real-Time RT-PCR
por: Shan, Ling, et al.
Publicado: (2015)

Microsatellite Status Detection of Colorectal Cancer: Evaluation of Inconsistency between PCR and IHC
por: Chen, Jielin, et al.
Publicado: (2023)

Dual drive coexistence of ALK rearrangement and KRAS mutation advanced lung adenocarcinoma and response to crizotinib
por: Zhu, You-Cai, et al.
Publicado: (2019)

The impacts of viral inactivating methods on quantitative RT-PCR for COVID-19
por: Wang, Yueying, et al.
Publicado: (2020)

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression
por: Chen, Rui-Lian, et al.
Publicado: (2018)

Coexistence of a novel CCNY-ALK and ATIC-ALK double-fusion in one patient with ALK-positive NSCLC and response to crizotinib: a case report
por: Wu, Xuan, et al.
Publicado: (2020)

Combination of conventional immunohistochemistry and qRT-PCR to detect ALK rearrangement
por: Shan, Ling, et al.
Publicado: (2014)

CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib
por: Du, Xue, et al.
Publicado: (2018)

Comparison of Next-Generation Sequencing and Ventana Immunohistochemistry in Detecting ALK Rearrangements and Predicting the Efficacy of First-Line Crizotinib in Patients with Advanced Non-Small Cell Lung Cancer
por: Zeng, Liang, et al.
Publicado: (2020)

L1198F Mutation Resensitizes Crizotinib to ALK by Altering the Conformation of Inhibitor and ATP Binding Sites
por: Li, Jian, et al.
Publicado: (2017)

Circulating microRNAs as novel biomarkers of ALK-positive non-small cell lung cancer and predictors of response to crizotinib therapy
por: Li, Liang-Liang, et al.
Publicado: (2017)

Successful Retreatment with Crizotinib After Crizotinib-Induced Liver Failure in ALK-Positive Advanced Lung Adenocarcinoma: A Case Report
por: Zhang, Xiangming, et al.
Publicado: (2023)

A duplex nested RT-PCR method for monitoring porcine epidemic diarrhea virus and porcine delta-coronavirus
por: Li, Chun Qi, et al.
Publicado: (2023)

Frequency of ALK Rearrangement by FISH Testing and its Correlation with ALK-IHC in Adenocarcinoma of Primary Lung Origin
por: Moatter, Samar, et al.
Publicado: (2018)

Crizotinib Exhibits Antitumor Activity by Targeting ALK Signaling not c-MET in Pancreatic Cancer
por: Yan, Hong Hua, et al.
Publicado: (2014)

Chest CT of COVID-19 in patients with a negative first RT-PCR test: Comparison with patients with a positive first RT-PCR test
por: Chen, Zu-Hua, et al.
Publicado: (2020)

Crizotinib-induced acute fatal liver failure in an Asian ALK-positive lung adenocarcinoma patient with liver metastasis: A case report
por: Zhang, Ying, et al.
Publicado: (2019)

Sequential therapy with crizotinib and a second-generation ALK inhibitor versus direct therapy of a second-generation ALK inhibitor in ALK-positive advanced lung cancer: a real-world study
por: Wei, Jingwen, et al.
Publicado: (2023)

Patient harboring a novel PIK3CA point mutation after acquired resistance to crizotinib in an adenocarcinoma with ROS1 rearrangement: A case report and literature review
por: Xu, Chun‐wei, et al.
Publicado: (2017)

A CT‐based radiomics model to predict subsequent brain metastasis in patients with ALK‐rearranged non–small cell lung cancer undergoing crizotinib treatment
por: Jiang, Yongluo, et al.
Publicado: (2022)

ALK-G1269A mutation in epithelioid inflammatory myofibroblastic sarcoma after progression on crizotinib: A case report
por: Xu, Xiaojing, et al.
Publicado: (2019)

NTRK gene aberrations in triple‐negative breast cancer: detection challenges using IHC, FISH, RT‐PCR, and NGS
por: Zito Marino, Federica, et al.
Publicado: (2023)

Case report: Durable response to alectinib in ALK-rearranged lung adenocarcinoma with acquired, crizotinib-resistant ALK C1156F mutation
por: Rao, Chuangzhou, et al.
Publicado: (2022)

ALK-driven tumors and targeted therapy: focus on crizotinib
por: Murga-Zamalloa, Carlos, et al.
Publicado: (2014)

Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation
por: Ogata, Misato, et al.
Publicado: (2018)

Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial
por: Yang, Yunpeng, et al.
Publicado: (2023)

Ventana abierta
por: Kaspé, Vladimir, 1910-1996
Publicado: (1995)

Ventanas adentro /
por: Zapata, Isabel
Publicado: (2002)

Ventana abierta
por: Cortazar, Enrique
Publicado: (1993)

Casas ventana /
por: Bahamón, Alejandro
Publicado: (2009)

Clinical benefit of continuing crizotinib therapy after initial disease progression in Chinese patients with advanced ALK-rearranged non-small-cell lung cancer
por: Hong, Xiangchan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_e75nsnskk6kvmrgcu499brl5u1